Xytis Pharmaceuticals, Fournier deal

Fournier granted Xytis an exclusive worldwide license to Anatibant (LF-16-0687MF) to treat traumatic brain injury. The non-peptide bradykinin B2 antagonist has completed Phase I testing and has Orphan...